Compare ANL & CHCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANL | CHCT |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate Investment Trusts |
| Sector | | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 611.1M | 514.6M |
| IPO Year | 2022 | 2015 |
| Metric | ANL | CHCT |
|---|---|---|
| Price | $13.13 | $15.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $18.00 |
| AVG Volume (30 Days) | 197.8K | ★ 316.3K |
| Earning Date | 04-10-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 11.07% |
| EPS Growth | N/A | ★ 134.78 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $121,195,000.00 |
| Revenue This Year | $36.02 | $9.06 |
| Revenue Next Year | N/A | $8.61 |
| P/E Ratio | ★ N/A | $126.00 |
| Revenue Growth | N/A | ★ 4.67 |
| 52 Week Low | $0.88 | $13.23 |
| 52 Week High | $17.25 | $19.17 |
| Indicator | ANL | CHCT |
|---|---|---|
| Relative Strength Index (RSI) | 57.09 | 27.19 |
| Support Level | $12.41 | $14.02 |
| Resistance Level | $13.29 | $17.45 |
| Average True Range (ATR) | 1.03 | 0.51 |
| MACD | -0.05 | -0.31 |
| Stochastic Oscillator | 52.04 | 6.80 |
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems, or other healthcare service providers in non-urban markets. The company derives the majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.